Trials / Completed
CompletedNCT05304533
A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants
An Open-label, 3-Arm, Parallel Design Pharmacokinetic Interaction Study Between MYK-224 and Cytochrome P450 3A4 Inhibitors Itraconazole and Verapamil in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of co-administration of itraconazole or verapamil on the drug levels of MYK-224 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MYK-224 | Specified dose on specified days |
| DRUG | Itraconazole | Specified dose on specified days |
| DRUG | Verapamil | Specified dose on specified days |
Timeline
- Start date
- 2022-04-21
- Primary completion
- 2022-11-14
- Completion
- 2022-11-29
- First posted
- 2022-03-31
- Last updated
- 2023-01-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05304533. Inclusion in this directory is not an endorsement.